iLEAD Senegal Laboratories

iLEAD’s network partner in Senegal has the following specialist laboratory facilities in Dakar at the Institute for Health Research, Epidemiological Surveillance and Training (IRESSEF):

  • Immunology (PBMC, Flow Cytometry, ELISA, Quantiferon TB Gold, ELISPOT, Luminex)
  • Molecular Biology
  • Virology
  • Bio-Safety Level 3 TB Lab
  • Mycobacteriology laboratory
  • Upcoming laboratory for Omics and Bioinformatics
  • General Laboratory (Clinical Chemistry, Immunochemistry, Haematology, Biochemistry, Bacteriology)
  • Proficiency Testing Lab on Early Infant Diagnosis and Viral Load
  • Biobank
  • Maintenance and metrology


Dakar, Senegal

Prof Mboup recently established non-profit laboratory organization, the Institut de Recherche en Santé, de Surveillance Epidémiologique et de Formation (IRESSEF) in the Diamniadio District near Dakar.

IRESSEF is dedicated to biomedical research, training and networking across Senegal, the West African and sub-Saharan region.  IRESSEF aims to continue providing support, policy guidance and recommendations to the Public Health Laboratories Network through the Directorate of Laboratories in the Ministry of Health in Senegal based in Dakar. Within the past 3 years, the Directorate is focused on services within a tiered laboratory infrastructure, responsible for regulation (reagents and tests), technical support and epidemiological surveillance across the public sector laboratories (80% coverage, through 140 laboratories). This is with input from the CDC and PATH to support the Global Health Security Agenda. IRESSEF is attached to 45 clinical sites for virology projects, and has extensive network collaborations and members with organizations and consortia across West Africa such as West African Global Health Access (WAGHA), West African Taskforce for the Control of Emerging and Re-emerging Infectious Diseases (WATER), West Africa Platform for HIV Intervention Research (WAPHIR) and West African Network for TB AIDS and Malaria (WANTAM). Other partners include several universities, local partners, pharmaceutical firms, foundations and organizations such as the WHO-UNAIDS, CDC, the European Commission, the European and Developing Countries Clinical Trials Partnership (EDCTP), German Agency for Technical Cooperation (GTZ), Wellcome Trust, GILEAD and, BMGF amongst others. The IRESSEF has laboratory capacity and infrastructure across diagnostic disciplines with established units of virology, bacteriology, immunology and molecular biology, as well as a biobank with state-of-the-art equipment for an effective management of samples for continued research.

IRESSEF emphasizes Quality Management Systems (QMS) and Good Laboratory Practice (GLP) components for their clinical diagnostic and research laboratories. They have implemented and standardized technical standard operating procedures (SOPs), laboratory management processes and biosafety procedures for critical laboratory assays. IRESEFF is enrolled in Proficiency Testing programs with the College of American Pathology (CAP), the United Kingdom National External Quality Assessment Program (UK-NEQAS), the Quality Assurance Systems International (QASI), and the National Institute of Health (NIH) Department of AIDS (DAIDS) Virology Quality Assurance program (VQA) and l’Agence nationale de recherches sur le sida et les hépatites virales (ANRS, France). This quality framework has enabled IRESEFF to further develop PT panels, manufacture and coordinate local laboratory proficiency testing (PT) programs via internal QA and EQA programs for HIV early infant diagnosis (EID) and HIV monitoring (CD4 and viral load) for many African countries and supports QMS strengthening, focusing on research training and quality improvement (RTQI). Through AFRIQUALAB, IRESSEF also supports more than 30 countries across Africa for Biochemistry, Hematology, Serology and TB EQA. Together with their clinical collaborators, IRESSEF ensures the rigorous requirements to support clinical trials in compliance with International Conference on Harmonization (ICH) guidelines; U.S. Federal regulations and ISO are in place. One such example in the HIV/AIDS biomedical research performed included natural history cohort studies on HIV-1 and HIV-2.  These cohort studies led to the discovery of HIV-2 infection by the IRESSEF team which, together with Harvard University, which evolved as one of the strongest HIV-2 research groups in the world.

Senegal Team

Professor Souleymane Mboup

Co-Investigator of iLEAD – PhD
Country Lead: Senegal

Professor Souleymane Mboup is a world-renowned researcher and professor. He is Head of the Bacteriology-Virology Laboratory at le Dantec Hospital in Dakar, which is a teaching hospital of Cheikh Anta Diop University. The Bacteriology-Virology Laboratory is Senegal’s reference laboratory, performing important research on HIV/AIDS and sexually transmitted diseases. Professor Mboup co-ordinates many activities, including at the national level with disease surveillance and monitoring programmes, and at the regional level with regional health networks.

He works with the West African Network of Excellence for TB, AIDS and Malaria (WANETAM) and is the co-ordinator for West Africa Project Fair’s (WAPF) HIV research and prevention efforts. WANETAM is a collaborating centre for both UNITAID and ASLM. Professor Mboup recently established a non-profit laboratory organisation – the Institut de Recherche en Santé, de Surveillance Epidémiologique et de Formation (IRESSEF) in the Diamniadio District near Dakar.

Maimouna Traoré-Mané

Finance Lead

Maimouna Traoré-Mané is the Financial and Administrative Program Manager at the Institut de Research en Sante de Surveillance Epidemiologique et de Formation (IRESSEF) in Dakar, Senegal, where she has been working for the past eight years to support the management of numerous Centers for Disease Control and Prevention (CDC) and other United States Government (USG) funded contracts and grants.

Ms. Traoré-Mané’s experience includes a Bachelor of Arts (B.A.) in Business Administration from Georgia State University (Atlanta, GA) and Masters in Financial Accountability from York University (Ontario, Canada).  Ms. Traoré-Mané has over 12 years of experience in financial management and banking. Prior to joining IRESSEF, Ms. Traoré-Mané worked as a Personal Banker at Bank of America and Accounts Manager for the Royal Bank of Canada, where she provided customer service support for accounts management and investment portfolios, and ensured compliance with banking and other financial regulations.

Dr Djibril Wade

Project Manager

Djibril Wade obtained a Master’s degree in Biology and a university diploma in Biological Retrovirology before being awarded a scholarship from the Belgian Directorate of Cooperation and Development to start a PhD at the University of Antwerp in Belgium.  During his PhD research, entitled “Evaluation and Decentralization of CD4 T-cell counting technologies in Senegal,” Djibril assisted with the implementation of a national CD4 Quality Control program and in the decentralization of CD4 monitoring in remote areas.

He obtained his PhD in Biomedical Sciences in June 2015 and is the author and co-author of eight papers published in international, peer-reviewed journals. During his post-doctoral research, he was involved in a Clinical Trial assessing the safety and immunogenicity of an Ebola vaccine. His research interests include diagnostic tools and correlates of immune protection from Infectious Diseases, especially HIV, Tuberculosis, Hepatitis and other Emerging and Neglected Tropical pathogens, including Ebola infection. He joined IRESSEF (Institute of Research in Health, Epidemiological Surveillance and Training) in August 2016. Djibril is the Project Manager for iLEAD Senegal.

Dr Moussa Sarr

Deputy Country Lead

Dr Moussa Sarr is a senior epidemiologist at Westat and Head of the Cooperation Group at IRESSEF.  Since 2010, Dr Sarr has worked with Professor Mboup and the US PEPFAR program to support laboratory capacity-building activities in sub-Saharan Africa, including the implementation of effective laboratory quality management systems, with external quality assurance (EQA) and EQA costing. Key objectives of this effort are to address existing challenges and gaps in HIV testing and to ensure access to high quality HIV diagnostics.

Dr Sarr also works with the Cheikh Anta Diop University and the US CDC Global Health Security Agenda (GHSA) Program to strengthen the laboratory system in Senegal, so that it can respond to infectious disease outbreaks, health threats and PHEICs on an ongoing basis. Dr Sarr is also co-principal investigator of the Demonstration HIV Pre-exposure Prophylaxis (PrEP) Project in Dakar, Senegal, which is funded by the Bill and Melinda Gates Foundation.